Actinium Pharmaceuticals (Delaware) (ATNM) vs Impact BioMedical (IBO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed Impact BioMedical (IBO) over the past year, losing 29.9% versus a loss of 47.4%. Impact BioMedical is the larger company by market cap ($36.3 million vs $34.6 million), about 1.0 times the size. On valuation, Impact BioMedical trades at a lower trailing P/E (0.4x vs 3.1x for Actinium Pharmaceuticals (Delaware)).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | IBO |
|---|---|---|
| Share price | $1.10 | $4.25 |
| Market cap | $34.59M | $36.31M |
| 1-day change | +1.85% | +3.41% |
| YTD return | -20.59% | -35.70% |
| 1-year return | -29.87% | -47.38% |
| 5-year return | -86.57% | — |
| P/E ratio (TTM) | 3.06 | 0.38 |
| EPS (TTM) | $0.36 | $11.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.74 | $10.51 |
| 52-week low | $0.735 | $4.06 |
| Distance from 52-week high | -36.78% | -59.55% |
| Analyst consensus | none | — |
| Avg. price target upside | +227.27% | — |
| Average volume | 139.78K | 11.85K |
| Shares outstanding | 31.44M | 8.54M |
| Employees | 27 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATNM has outperformed IBO by 17.5 percentage points over the past year.
- Actinium Pharmaceuticals (Delaware) trades at a higher earnings multiple (3.1x vs 0.4x trailing P/E).
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Impact BioMedical
IBO stock →Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
ATNM vs IBO FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or Impact BioMedical?
Impact BioMedical (IBO) is larger, with a market capitalization of $36.31M compared with $34.59M for Actinium Pharmaceuticals (Delaware) (ATNM).
Which stock has performed better over the past year, ATNM or IBO?
ATNM returned -29.87% over the past 12 months, compared with -47.38% for IBO (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ATNM or IBO?
IBO has the lower trailing P/E at 0.4, versus 3.1 for ATNM. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Actinium Pharmaceuticals (Delaware) and Impact BioMedical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.